<DOC>
	<DOC>NCT02480894</DOC>
	<brief_summary>This is a Phase 1, open-label, single sequence, two-way interaction study in healthy male and female subjects. - For the effect of maraviroc on the PK of BMS-626529 (the active moiety of BMS-663068), there is no formal hypothesis to be statistically tested. The purpose of this assessment is to estimate the effect of maraviroc on the pharmacokinetics (PK) of BMS-626529 when coadministered in healthy subjects. - For the effect of BMS-663068 on the PK of maraviroc, the hypothesis to be statistically tested is that BMS-663068 will not have a clinically significant effect on the PK of maraviroc when coadministered in healthy subjects.</brief_summary>
	<brief_title>A Open-label, Drug-Drug Interaction With Maraviroc</brief_title>
	<detailed_description />
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Healthy male and female nonsmoking subjects ages 18 to 50 years, inclusive with a body mass index of 18.0 to 32.0 kg/m2, inclusive Women of childbearing potential must agree to follow instructions for methods of contraception for a total of 34 days posttreatment completion Any condition possibly affecting drug absorption Preexisting liver dysfunction Any significant acute or chronic medical illness Orthostatic intolerance Other protocol specified exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>